In Vitro Activity of Telavancin Against Clinically Important Gram-Positive Pathogens from 69 U.S. Medical Centers (2015): Potency Analysis by U.S. Census Divisions.

A total of 8,072 gram-positive isolates collected from 69 medical centers among all 9 U.S. Census Divisions during the 2015 SENTRY Antimicrobial Surveillance Program were included. Telavancin had minimal inhibitory concentration (MIC)50 and MIC90 values of 0.03/0.06 μg/mL, respectively, against methicillin-susceptible (MSSA) and methicillin-resistant Staphylococcus aureus (MRSA). Similar activity was also observed among coagulase-negative staphylococci (MIC50/90, 0.03/0.06 μg/ml; 100.0% inhibited by ≤0.12 μg/ml). Telavancin was active against vancomycin-susceptible Enterococcus faecalis (MIC50/90, 0.12/0.12 μg/ml) and Enterococcus faecium (MIC50/90, 0.03/0.06 μg/ml), but was less active against vancomycin-resistant E. faecium (MIC90, >2 μg/ml) and E. faecalis (MIC90, >2 μg/ml). Streptococci showed modal MIC results of 0.008 μg/ml (Streptococcus pneumoniae) to 0.015 μg/ml (β-hemolytic streptococci and viridans group streptococci). Potency variations for telavancin within Census Divisions were not observed. Telavancin remains potent in vitro against indicated pathogens recovered from U.S. medical centers (2015).